Corpus Intelligence IC Memo — NORTHWEST SPECIALTY HOSPITAL 2026-04-26 05:29 UTC
IC Memo — NORTHWEST SPECIALTY HOSPITAL
Investment Committee Memorandum | ID | 32 beds | Grade C | EBITDA uplift $8.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NORTHWEST SPECIALTY HOSPITAL

CCN 130066 | KOOTENAI, ID | 32 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NORTHWEST SPECIALTY HOSPITAL is a 32-bed suburban community hospital in KOOTENAI, ID with $120.3M in net patient revenue and a 3.7% operating margin. The hospital serves a payer mix of 35.1% Medicare, 5.3% Medicaid, and 59.6% commercial.

Thesis: Turnaround. Our ML models identify $8.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 3.7% to 11.1% (+736bps).

Net Revenue HCRIS$120.3M
Current EBITDA COMPUTED$4.5M
Operating Margin COMPUTED3.7%
Occupancy HCRIS19.7%
Revenue / Bed COMPUTED$3.8M
Net-to-Gross HCRIS30.1%
Distress Probability ML51.8%

2. Market Context & Competitive Position

51
ID Hospitals
-3.5%
State Median Margin
27
Comparable Hospitals

ID has 51 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 3.7% places it above the state median. Among 27 size-comparable peers (16-64 beds), the median margin is -2.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (16-64), prioritizing same-state peers. 27 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NORTHWEST SPECIALTY HOSPITAL (Target)ID32$120.3M3.7%
MOUNTAIN VIEW HOSPITALID43$382.5M8.7%
BINGHAM MEMORIAL HOSPITALID25$164.8M-3.6%
TREASURE VALLEY HOSPITALID28$114.8M36.1%
ST. LUKES WOOD RIVER MEDICAL CID25$99.1M13.5%
MADISON MEMORIAL HOSPITALID53$94.0M1.1%
GRITMAN MEDICAL CENTERID25$92.4M-6.4%
BONNER GENERAL HOSPITALID25$61.2M-7.6%
NORTH CANYON MEDICAL CENTERID16$53.7M4.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.5M+210bp18mo
Cost to Collect4.5%2.5%$2.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.5M+122bp9mo
Clean Claim Rate88.0%96.0%$77K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.5M
Cost to Collect
$2.4M
Denial Rate Reduction
$2.4M
A/R Days Reduction
$1.5M
Clean Claim Rate
$77K
Total EBITDA Uplift$8.9M
Current EBITDA$4.5M
+ RCM Uplift+$8.9M
Pro Forma EBITDA$13.3M
Current Margin3.7%
Pro Forma Margin11.1%
WC Released (1x)$4.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$6.9M$118.2M17.10x76.4%
Base (11x exit)10.0x11.0x$6.9M$132.2M19.14x80.5%
Bull Case9.0x11.0x$6.2M$163.7M26.32x92.3%
Bull (12x exit)9.0x12.0x$6.2M$180.4M29.01x96.1%
Bear Case11.0x10.0x$7.6M$71.6M9.43x56.6%
Bear (11x exit)11.0x11.0x$7.6M$81.3M10.69x60.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 19.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 51.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 27 hospitals with 16-64 beds
  • Same-state prioritization (n=28)
  • Comp margins: P25=-6.8% / P50=-2.8% / P75=1.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.